Skip to main content

Important Safety Information

Important Safety Information

CIMERLI® (ranibizumab-eqrn) is interchangeable* to Lucentis® (ranibizumab injection).

What important safety information should I know about CIMERLI®?

  • You should not receive CIMERLI® if you have an infection in or around the eye or are allergic to CIMERLI® or any of its ingredients. CIMERLI® is a prescription medication given by injection into the eye, and it has side effects. CIMERLI® is not for everyone. Some patients using ranibizumab products have had detached retinas and serious eye infections. If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away
  • Some patients have had increased eye pressure before and within 1 hour of an injection. Your eye doctor should check your eye pressure and eye health before and after your CIMERLI® injection
  • Uncommonly, patients using ranibizumab products have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes. Although the rate of fatal events were low, they were more common in diabetic patients
  • Some patients using ranibizumab products have serious side effects related to the injection. These include serious infections inside the eye and detached retinas. The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non-eye-related side effects are nose and throat infections, anemia, nausea, and cough
  • Reports of a tear in the outermost layer of the retina in patients with neovascular AMD (age-related macular degeneration) have been reported after treatment with ranibizumab products
  • CIMERLI® is for prescription use only

*An interchangeable product (IP) is a biological product that is approved based on data demonstrating that it is highly similar to an FDA-approved reference product (RP) and that there are no clinically meaningful differences between the products; it can be expected to produce the same clinical result as the RP in any given patient; and if administered more than once to a patient, the risk in terms of safety or diminished efficacy from alternating or switching between use of the RP and IP is not greater than that from the RP without such alternation or switch. Patients taking CIMERLI® can expect similar clinical results and side effects as the reference product Lucentis®. Interchangeability of CIMERLI® has been demonstrated for the condition(s) of use, strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information.

You may report side effects to Coherus BioSciences at 1-800-483-3692 or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch (opens in a new tab).

For additional Safety Information, please talk to your doctor and see the CIMERLI® Full Prescribing Information (opens in a new tab).

Indications

Who is CIMERLI® for?

CIMERLI® is a prescription medicine for the treatment of patients with:

  • wet age-related macular degeneration (wAMD)
  • diabetic retinopathy and diabetic macular edema (DR and DME)
  • myopic choroidal neovascularization (mCNV)
  • macular edema following retinal vein occlusion (RVO)

Important Safety Information

Important Safety Information

CIMERLI® (ranibizumab-eqrn) is interchangeable* to Lucentis® (ranibizumab injection).

What important safety information should I know about CIMERLI®?

  • You should not receive CIMERLI® if you have an infection in or around the eye or are allergic to CIMERLI® or any of its ingredients. CIMERLI® is a prescription medication given by injection into the eye, and it has side effects. CIMERLI® is not for everyone. Some patients using ranibizumab products have had detached retinas and serious eye infections. If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away
  • Some patients have had increased eye pressure before and within 1 hour of an injection. Your eye doctor should check your eye pressure and eye health before and after your CIMERLI® injection
  • Uncommonly, patients using ranibizumab products have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes. Although the rate of fatal events were low, they were more common in diabetic patients
  • Some patients using ranibizumab products have serious side effects related to the injection. These include serious infections inside the eye and detached retinas. The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non-eye-related side effects are nose and throat infections, anemia, nausea, and cough
  • Reports of a tear in the outermost layer of the retina in patients with neovascular AMD (age-related macular degeneration) have been reported after treatment with ranibizumab products
  • CIMERLI® is for prescription use only

*An interchangeable product (IP) is a biological product that is approved based on data demonstrating that it is highly similar to an FDA-approved reference product (RP) and that there are no clinically meaningful differences between the products; it can be expected to produce the same clinical result as the RP in any given patient; and if administered more than once to a patient, the risk in terms of safety or diminished efficacy from alternating or switching between use of the RP and IP is not greater than that from the RP without such alternation or switch. Patients taking CIMERLI® can expect similar clinical results and side effects as the reference product Lucentis®. Interchangeability of CIMERLI® has been demonstrated for the condition(s) of use, strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information.

You may report side effects to Coherus BioSciences at 1-800-483-3692 or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch (opens in a new tab).

For additional Safety Information, please talk to your doctor and see the CIMERLI® Full Prescribing Information (opens in a new tab).

Indications

Who is CIMERLI® for?

CIMERLI® is a prescription medicine for the treatment of patients with:

  • wet age-related macular degeneration (wAMD)
  • diabetic retinopathy and diabetic macular edema (DR and DME)
  • myopic choroidal neovascularization (mCNV)
  • macular edema following retinal vein occlusion (RVO)

Important Safety Information

CIMERLI® (ranibizumab-eqrn) is interchangeable* to Lucentis® (ranibizumab injection).

What important safety information should I know about CIMERLI®?

  • You should not receive CIMERLI® if you have an infection in or around the eye or are allergic to CIMERLI® or any of its ingredients. CIMERLI® is a prescription medication given by injection into the eye, and it has side effects. CIMERLI® is not for everyone. Some patients using ranibizumab products have had detached retinas and serious eye infections. If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away
  • Some patients have had increased eye pressure before and within 1 hour of an injection. Your eye doctor should check your eye pressure and eye health before and after your CIMERLI® injection
  • Uncommonly, patients using ranibizumab products have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes. Although the rate of fatal events were low, they were more common in diabetic patients
  • Some patients using ranibizumab products have serious side effects related to the injection. These include serious infections inside the eye and detached retinas. The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non-eye-related side effects are nose and throat infections, anemia, nausea, and cough
  • Reports of a tear in the outermost layer of the retina in patients with neovascular AMD (age-related macular degeneration) have been reported after treatment with ranibizumab products
  • CIMERLI® is for prescription use only

*An interchangeable product (IP) is a biological product that is approved based on data demonstrating that it is highly similar to an FDA-approved reference product (RP) and that there are no clinically meaningful differences between the products; it can be expected to produce the same clinical result as the RP in any given patient; and if administered more than once to a patient, the risk in terms of safety or diminished efficacy from alternating or switching between use of the RP and IP is not greater than that from the RP without such alternation or switch. Patients taking CIMERLI® can expect similar clinical results and side effects as the reference product Lucentis®. Interchangeability of CIMERLI® has been demonstrated for the condition(s) of use, strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information.

You may report side effects to Coherus BioSciences at 1-800-483-3692 or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch (opens in a new tab).

For additional Safety Information, please talk to your doctor and see the CIMERLI® Full Prescribing Information (opens in a new tab).

Important Safety Information

Important Safety Information

CIMERLI® (ranibizumab-eqrn) is interchangeable* to Lucentis® (ranibizumab injection).

What important safety information should I know about CIMERLI®?

  • You should not receive CIMERLI® if you have an infection in or around the eye or are allergic to CIMERLI® or any of its ingredients. CIMERLI® is a prescription medication given by injection into the eye, and it has side effects. CIMERLI® is not for everyone. Some patients using ranibizumab products have had detached retinas and serious eye infections. If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away
  • Some patients have had increased eye pressure before and within 1 hour of an injection. Your eye doctor should check your eye pressure and eye health before and after your CIMERLI® injection
  • Uncommonly, patients using ranibizumab products have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes. Although the rate of fatal events were low, they were more common in diabetic patients
  • Some patients using ranibizumab products have serious side effects related to the injection. These include serious infections inside the eye and detached retinas. The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non-eye-related side effects are nose and throat infections, anemia, nausea, and cough
  • Reports of a tear in the outermost layer of the retina in patients with neovascular AMD (age-related macular degeneration) have been reported after treatment with ranibizumab products
  • CIMERLI® is for prescription use only

*An interchangeable product (IP) is a biological product that is approved based on data demonstrating that it is highly similar to an FDA-approved reference product (RP) and that there are no clinically meaningful differences between the products; it can be expected to produce the same clinical result as the RP in any given patient; and if administered more than once to a patient, the risk in terms of safety or diminished efficacy from alternating or switching between use of the RP and IP is not greater than that from the RP without such alternation or switch. Patients taking CIMERLI® can expect similar clinical results and side effects as the reference product Lucentis®. Interchangeability of CIMERLI® has been demonstrated for the condition(s) of use, strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information.

You may report side effects to Coherus BioSciences at 1-800-483-3692 or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch (opens in a new tab).

For additional Safety Information, please talk to your doctor and see the CIMERLI® Full Prescribing Information (opens in a new tab).

Indications

Who is CIMERLI® for?

CIMERLI® is a prescription medicine for the treatment of patients with:

  • wet age-related macular degeneration (wAMD)
  • diabetic retinopathy and diabetic macular edema (DR and DME)
  • myopic choroidal neovascularization (mCNV)
  • macular edema following retinal vein occlusion (RVO)

Indications

Indications

Who is CIMERLI® for?

CIMERLI® is a prescription medicine for the treatment of patients with:

  • wet age-related macular degeneration (wAMD)
  • diabetic retinopathy and diabetic macular edema (DR and DME)
  • myopic choroidal neovascularization (mCNV)
  • macular edema following retinal vein occlusion (RVO)

You are now
leaving CIMERLI.com

Coherus BioSciences is not responsible for the content of linked third-party websites. Please be aware that the privacy policies and terms of use on these sites are different from Coherus BioSciences policies.

Cancel Leave Site (opens in a new tab)

Please select which best describes you:

Healthcare Professional Patient or Caregivers

You are about to visit a website that contains clinical information created specifically for healthcare professionals.

If you are not a healthcare professional and would like to remain on the patient site, please click CANCEL.

Cancel Continue (opens in a new tab)